U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Inspections, Compliance, Enforcement, and Criminal Investigations
  3. Compliance Actions and Activities
  4. Warning Letters
  5. Central Admixture Pharmacy Services Inc - 497021 - 05/27/2020
  1. Warning Letters

CLOSEOUT LETTER

Central Admixture Pharmacy Services Inc MARCS-CMS 497021 —

Product:
Drugs
Recipient:
Recipient Name
Thomas J. Wilverding
Recipient Title
President
Central Admixture Pharmacy Services Inc

6800 Aston Street
Suite 150
Irvine, CA 92606
United States

Issuing Office:
Division of Pharmaceutical Quality Operations IV

United States

(949) 608-2900

Dear Mr. Wilverding:

The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firm’s corrective actions in response to our warning letter # 40-16, issued August 18, 2016. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.

You are expected to take all necessary steps to ensure compliance with the Federal Food, Drug, and Cosmetic Act and FDA’s implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.

Sincerely,
/S/
CDR Steven E. Porter, Jr.
Director, Division of Pharmaceutical Quality Operations IV

Back to Top